CLRS

Clearsign Technologies carries an Underweight rating with 1/5 conviction, based on a 31.9 composite score and a sharply uneven pillar profile. Regulatory is the strongest contribution at 50.0, supported by a 55.0 jurisdiction score and an 80.0 enforcement subscore. Market contributes 40.0 despite unavailable institutional pricing feeds, while editorial contributes 30.0 amid no identified newsroom or brief activity. Fundamentals rank last at 14.0, reflecting weak growth, deeply negative profitability, modest scale, and a stretched financial condition. The resulting mix places the company firmly in the Underweight band, with regulatory standing as the only pillar reaching the midpoint.

Licensed fundamentals data show year-over-year revenue contracting by roughly 52%, leaving the revenue-growth subscore at zero. Gross margin is approximately 17%, translating into a 27.7 subscore, while the operating margin is near negative 1,193%, producing no operating-margin contribution. Net income is a loss of about $5.6 million, and EBITDA is negative by roughly $6.5 million, confirming that operating losses remain severe rather than offsetting the stretched condition. A market capitalization near $23.5 million contributes a 14.8 scale subscore, while the cash-runway subscore of 39.5 offers limited support without reversing the broader weakness. Primary regulatory filings show no latest filing date, no regulatory events during either the latest 90-day or 180-day period, and no enforcement hits; that combination supports the 80.0 enforcement score but leaves cadence at only 25.0. CIN newsroom coverage records no newsroom hits or briefs.

The forward catalyst rests entirely on the regulatory pillar because it carries the highest score and the clearest path to incremental improvement. A renewed sequence of primary regulatory filings would directly address the weak cadence subscore, validate continued corporate activity, and strengthen the only pillar already positioned above the remaining three. Regulatory progress alone does not repair contracting revenue, negative EBITDA, the net loss, or the stretched financial condition, but documented filing activity enables a more credible reassessment of execution. The single most important signal to watch is the appearance of a current primary regulatory filing that re-establishes filing cadence.